DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

The company’s wholly owned program, DNL310 or tividenofusp alfa, is an Enzyme Transport Vehicle-enabled iduronate-2-sulfatase (IDS) replacement therapy in development for MPS II (Hunter syndrome).

Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $32.00. Thomas Shrader’s rating is based on Denali ...

Riad Sattouf’s saga of his parents’ failed bicultural marriage, with its harsh depiction of life in rural Syria, has become a literary sensation. By Richard Fausset A popular TV host ...

The Walt Disney Company operates as an entertainment company worldwide. It operates through three segments: Entertainment, Sports, and Experiences. The company produces and distributes film and ...

Hundreds of truckloads of food, fuel and other supplies have arrived in Gaza each day since the cease-fire took effect. But the need is vast after 15 months of war. By Vivian Yee and Bilal ...

Jan. 24, 2025 — We're nearly one month into 2025, but if you're struggling to hold onto your New Year's resolution, stay strong, as new research shows that forming a healthy habit can take ...